Sudarshan Pharma [SUDARSHAN] vs Tata Chemicals [TATACHEM] Detailed Stock Comparison
Sudarshan Pharma
BSE
Loading...
Tata Chemicals
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma wins in 7 metrics, Tata Chemicals wins in 11 metrics, with 0 ties. Tata Chemicals appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma | Tata Chemicals | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.86 | 75.13 | Sudarshan Pharma |
| Price-to-Book Ratio | 4.76 | 1.11 | Tata Chemicals |
| Debt-to-Equity Ratio | 129.85 | 31.43 | Tata Chemicals |
| PEG Ratio | N/A | 1.11 | N/A |
| EV/EBITDA | 16.49 | 15.56 | Tata Chemicals |
| Profit Margin (TTM) | 3.83% | 2.27% | Sudarshan Pharma |
| Operating Margin (TTM) | 6.99% | 9.92% | Tata Chemicals |
| EBITDA Margin (TTM) | 6.99% | 9.92% | Tata Chemicals |
| Return on Equity | 12.13% | 2.17% | Sudarshan Pharma |
| Return on Assets (TTM) | 3.96% | 0.62% | Sudarshan Pharma |
| Free Cash Flow (TTM) | $304.76M | $-2.44B | Sudarshan Pharma |
| Dividend Yield | N/A | 1.19% | N/A |
| 1-Year Return | -93.27% | -21.67% | Tata Chemicals |
| Price-to-Sales Ratio (TTM) | 1.13 | 1.61 | Sudarshan Pharma |
| Enterprise Value | $7.94B | $301.60B | Tata Chemicals |
| EV/Revenue Ratio | 1.44 | 2.04 | Sudarshan Pharma |
| Gross Profit Margin (TTM) | 11.05% | 68.11% | Tata Chemicals |
| Revenue per Share (TTM) | $23 | $582 | Tata Chemicals |
| Earnings per Share (Diluted) | $0.87 | $12.49 | Tata Chemicals |
| Beta (Stock Volatility) | 0.68 | 0.44 | Tata Chemicals |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sudarshan Pharma vs Tata Chemicals Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | 4.99% | 4.88% | -15.13% | -6.93% | -11.29% | -38.71% |
| Tata Chemicals | -0.51% | 0.15% | -1.75% | -0.26% | 15.77% | -10.75% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | -93.27% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
| Tata Chemicals | -21.67% | -18.97% | 189.93% | 404.30% | 387.25% | 1,018.72% |
News Based Sentiment: Sudarshan Pharma vs Tata Chemicals
Sudarshan Pharma
News based Sentiment: NEGATIVE
Sudarshan Pharma faces significant headwinds, including a substantial year-to-date stock decline, negative analyst ratings predicting a 48% decline, and concerning valuation metrics. While the upcoming IPO presents a potential opportunity, the overall narrative is one of caution and risk, making this a pivotal moment for the company.
Tata Chemicals
News based Sentiment: MIXED
October presented a mixed bag for Tata Chemicals with fluctuating financials, leadership changes, and the broader Tata Group's significant investment in semiconductors. While the company faces short-term revenue challenges, positive analyst sentiment and a favorable trade agreement offer potential for future growth, making it a cautiously optimistic investment.
Performance & Financial Health Analysis: Sudarshan Pharma vs Tata Chemicals
| Metric | SUDARSHAN | TATACHEM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.56B | ₹236.62B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 53,200 | 768,531 |
| 90 Day Avg. Volume | 77,333 | 602,404 |
| Last Close | ₹28.63 | ₹922.00 |
| 52 Week Range | ₹24.69 - ₹53.50 | ₹756.00 - ₹1,247.35 |
| % from 52W High | -46.49% | -26.08% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹1,349.00 (Mar 04, 2024) |
| % from All-Time High | -93.68% | -31.65% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | -0.02% |
| Quarterly Earnings Growth | N/A | 0.68% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.02% |
| Operating Margin (TTM) | 0.07% | 0.10% |
| Return on Equity (TTM) | 0.12% | 0.02% |
| Debt to Equity (MRQ) | 129.85 | 31.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.46 | ₹847.63 |
| Cash per Share (MRQ) | ₹0.09 | ₹54.98 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹11.31B |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹2.35B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.19% |
| Last 12-Month Dividend | N/A | ₹11.00 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma vs Tata Chemicals
| Metric | SUDARSHAN | TATACHEM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.86 | 75.13 |
| Forward P/E | N/A | 19.02 |
| PEG Ratio | N/A | 1.11 |
| Price to Sales (TTM) | 1.13 | 1.61 |
| Price to Book (MRQ) | 4.76 | 1.11 |
| Market Capitalization | ||
| Market Capitalization | ₹6.56B | ₹236.62B |
| Enterprise Value | ₹7.94B | ₹301.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 2.04 |
| Enterprise to EBITDA | 16.49 | 15.56 |
| Risk & Other Metrics | ||
| Beta | 0.68 | 0.44 |
| Book Value per Share (MRQ) | ₹5.46 | ₹847.63 |
Financial Statements Comparison: Sudarshan Pharma vs Tata Chemicals
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUDARSHAN | TATACHEM |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹37.19B |
| Cost of Goods Sold | ₹1.29B | ₹11.86B |
| Gross Profit | ₹160.46M | ₹25.33B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹101.60M | ₹3.69B |
| EBITDA | ₹122.50M | ₹7.87B |
| Pre-Tax Income | ₹54.09M | ₹3.60B |
| Income Tax | ₹14.51M | ₹440.00M |
| Net Income (Profit) | ₹39.59M | ₹3.16B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUDARSHAN | TATACHEM |
|---|---|---|
| Cash & Equivalents | ₹5.51M | ₹5.48B |
| Total Current Assets | ₹3.35B | ₹67.20B |
| Total Current Liabilities | ₹2.60B | ₹61.39B |
| Long-Term Debt | ₹104.60M | ₹48.16B |
| Total Shareholders Equity | ₹1.31B | ₹225.01B |
| Retained Earnings | N/A | ₹92.79B |
| Property, Plant & Equipment | ₹200.50M | ₹4.31B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUDARSHAN | TATACHEM |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | TATACHEM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 53,200 | 768,531 |
| Average Daily Volume (90 Day) | 77,333 | 602,404 |
| Shares Outstanding | 240.66M | 254.76M |
| Float Shares | 71.19M | 156.06M |
| % Held by Insiders | 0.76% | 0.39% |
| % Held by Institutions | 0.00% | 0.30% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma vs Tata Chemicals
| Metric | SUDARSHAN | TATACHEM |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹11.00 |
| Last 12-Month Dividend Yield | N/A | 1.19% |
| 3-Year Avg Annual Dividend | N/A | ₹14.50 |
| 3-Year Avg Dividend Yield | N/A | 1.45% |
| 3-Year Total Dividends | N/A | ₹43.50 |
| Ex-Dividend Date | N/A | Jun 12, 2025 |